Bone Competitors
| BBLG Stock | USD 1.69 0.02 1.20% |
Bone Biologics vs Biodexa Pharmaceticals Correlation
Poor diversification
The correlation between Bone Biologics Corp and BDRX is 0.6 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Bone Biologics Corp and BDRX in the same portfolio, assuming nothing else is changed.
Moving against Bone Stock
| 0.66 | 301367 | BMC Medical | PairCorr |
| 0.54 | 301370 | GKHT Medical Technology | PairCorr |
| 0.46 | 002382 | Blue Sail Medical | PairCorr |
| 0.37 | 688198 | Beijing Balance Medical | PairCorr |
| 0.37 | HOLX | Hologic Earnings Call This Week | PairCorr |
Bone Biologics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bone Biologics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bone and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bone Biologics Corp does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Bone Stock performing well and Bone Biologics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bone Biologics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HSCS | 4.24 | 0.18 | 0.02 | (1.11) | 5.03 | 11.07 | 26.18 | |||
| VERO | 15.22 | 4.38 | 0.31 | (2.17) | 10.51 | 8.14 | 516.97 | |||
| NAOV | 5.98 | (0.10) | 0.00 | (2.18) | 0.00 | 10.43 | 93.37 | |||
| DHAI | 65.52 | 29.26 | 0.61 | (1.03) | 27.94 | 193.55 | 976.19 | |||
| MOVE | 10.88 | 3.30 | 0.45 | 1.11 | 6.27 | 16.73 | 164.71 | |||
| NDRA | 5.11 | (0.16) | 0.00 | (0.08) | 0.00 | 12.24 | 38.62 | |||
| GCTK | 4.62 | (1.48) | 0.00 | (0.54) | 0.00 | 8.36 | 34.35 | |||
| VTAK | 4.71 | (0.28) | 0.00 | (0.07) | 0.00 | 13.33 | 35.41 | |||
| INM | 4.33 | (0.92) | 0.00 | (0.40) | 0.00 | 7.48 | 30.84 | |||
| BDRX | 8.88 | (0.93) | 0.00 | (0.30) | 0.00 | 11.45 | 128.35 |
Cross Equities Net Income Analysis
Compare Bone Biologics Corp and related stocks such as Heart Test Laboratories, Venus Concept, and NAOV Old Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HSCS | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (2.5 M) | (4.8 M) | (6.4 M) | (6.6 M) | (8.8 M) | (7.9 M) | (8.3 M) |
| VERO | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (21.8 M) | (17.8 M) | (28.7 M) | (42.3 M) | (82.8 M) | (22.1 M) | (43.7 M) | (37.2 M) | (47 M) | (42.3 M) | (44.4 M) |
| DHAI | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (10.9 M) | (12.1 M) | (2.4 M) | (8.4 M) | (8.4 M) | (8.7 M) | (9.1 M) |
| MOVE | 545 K | 7.3 M | 5.6 M | 574 K | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (8.4 M) | (14 M) | (22.6 M) | (30.2 M) | (29.3 M) | (23.7 M) | (21.4 M) | (20.3 M) |
| NDRA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.3 M) | (2.8 M) | (5.4 M) | (9.8 M) | (13.3 M) | (11.7 M) | (11.2 M) | (13.2 M) | (10.1 M) | (11.5 M) | (10.4 M) | (10.9 M) |
| GCTK | (1.2 M) | (2.4 M) | (2.8 M) | (9.8 M) | 3 M | (5.8 M) | (5.4 M) | (10.3 M) | (6.7 M) | (3.5 M) | (2.7 M) | (4.1 M) | (4.4 M) | (7.1 M) | (22.6 M) | (20.3 M) | (19.3 M) |
| VTAK | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (17.8 M) | (30.8 M) | (57 M) | (36 M) | (25.1 M) | (26.9 M) | (70.6 M) | (16.6 M) | (15 M) | (15.7 M) |
| INM | (4.3 M) | (189.9 K) | (46.7 K) | (1.2 M) | (3.5 M) | (1.8 M) | (3.4 M) | (6.7 M) | (10 M) | (8.9 M) | (12.6 M) | (18.6 M) | (7.9 M) | (7.7 M) | (8.2 M) | (7.3 M) | (7 M) |
| BDRX | (4 M) | (4 M) | (4 M) | (4.1 M) | (8.8 M) | (10.1 M) | (6.2 M) | (11.7 M) | (10.4 M) | (10.1 M) | (22.2 M) | (5.5 M) | (7.7 M) | (7.1 M) | (5.7 M) | (5.2 M) | (5.4 M) |
Bone Biologics Corp and related stocks such as Heart Test Laboratories, Venus Concept, and NAOV Old Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Bone Biologics Corp financial statement analysis. It represents the amount of money remaining after all of Bone Biologics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Bone Biologics Competitive Analysis
The better you understand Bone Biologics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bone Biologics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bone Biologics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Bone Biologics Competition Performance Charts
Five steps to successful analysis of Bone Biologics Competition
Bone Biologics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bone Biologics Corp in relation to its competition. Bone Biologics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Bone Biologics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bone Biologics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bone Biologics Corp, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Bone Biologics position
In addition to having Bone Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Absolute Returns ETFs Thematic Idea Now
Absolute Returns ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Absolute Returns ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Absolute Returns ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bone Biologics Correlation with its peers. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Can Health Care Equipment & Supplies industry sustain growth momentum? Does Bone have expansion opportunities? Factors like these will boost the valuation of Bone Biologics. Projected growth potential of Bone fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Bone Biologics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bone Biologics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bone Biologics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bone Biologics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.